Open AccessS197: NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR‐NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN‐LABEL PHASE 2 STUDY
Author(s) -
Passamonti F.,
Foran J.,
Tandra A.,
De Stefano V.,
Laura Fox M.,
Mattour A.,
McMullin M. F.,
Perkins A. C.,
RodriguezMacías G.,
Sibai H.,
Qin Q.,
Potluri J.,
How J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843680.94912.c5
Subject(s) - ruxolitinib , medicine , myelofibrosis , phases of clinical research , clinical endpoint , clinical trial , oncology , pharmacology , gastroenterology , bone marrow